Irinotecan (Camptosar, Onivyde)
Chemotherapy · Approved since 1996
Topoisomerase I
Description
Irinotecan (Camptosar) es un quimioterapico fundamental en CCR metastasico. Como agente unico en segunda linea: ORR 18%, SLP 4.2mo. Combinado con 5-FU (FOLFIRI): ORR 44%, SLP 7.6mo, SG 17.4mo.
Mechanism of Action
Irinotecan es un inhibidor de topoisomerasa I que impide la religacion del ADN durante la replicacion, causando roturas de cadena simple letales.
Molecular Targets
Side Effects
Diarrhea
Neutropenia
Nausea
Vomiting
Fatigue
Alopecia
Abdominal pain
Anorexia
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06197425
Phase 3
Recruiting
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
France
NCT07415031
Phase 2
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
United States, Australia, Belgium, Canada, France, Germany, Greece, Israel, Ital
NCT07446322
Phase 2
Recruiting
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
United States
NCT07221357
Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Ch
NCT07389265
Phase 3
Recruiting
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
Italy, Spain
NCT07011576
Phase 2
Recruiting
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
United States
Quick Info
| Brand Name | Camptosar, Onivyde |
| Category | Chemotherapy |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS approved in CRC |
| Administration | IV |
| Year Approved | 1996 |
| Clinical Trials | 471 |
Regimens with this Drug
FOLFIRI
Fluorouracil + Leucovorin + Irinotecan
1st line, 2nd line
FOLFOXIRI
Fluorouracil + Leucovorin + Oxaliplatin + Irinotecan
1st line
FOLFIRI + Bev
Fluorouracil + Leucovorin + Irinotecan + Bevacizumab
1st line, 2nd line
FOLFIRI + Cetux
Fluorouracil + Leucovorin + Irinotecan + Cetuximab
1st line, 2nd line
FOLFIRI + Pani
Fluorouracil + Leucovorin + Irinotecan + Panitumumab
1st line, 2nd line
FOLFOXIRI + Bev
Fluorouracil + Leucovorin + Oxaliplatin + Irinotecan + Bevacizumab
1st line
Related Medications
Doxorubicin
Other Medications
5 trials
Nktr
Other Medications
4 trials
Nktr-
Antibody-Drug Conjugate
4 trials
Naliri
Other Medications
3 trials
NALIRIFOX
Other Medications
2 trials
Mm-398
Other Medications
2 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.